CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
Recruiting now · Phase 1/Phase 2
Conditions studied: T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)
In brief
This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD5 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD5 CAR T cell bridging to HSCT in the treatment of r/r T-NHL. The primary endpoint is the type and incidence of dose limiting toxicity (DLT) within 21 days after CD5 CAR-T cell infusion. A total of 36 subjects is estimated to be enrolled.
Key facts
- Study ID
- NCT07022964
- Run by
- Beijing GoBroad Hospital
- People needed
- 36
- Starts
- 2025-06-01
- Expected to finish
- 2028-06-01
- Last updated by the study team
- 2025-06-15
Who can join
Age: 14 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Beijing GoBroad Hospital — Beijing, China (enrolling)
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine — Shanghai, China (enrolling)
- Shanghai Liquan Hospital — Shanghai, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.